Zhou, Na
(Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, People's Republic of China)
,
Zhang, Chuan‐Tao
(Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, People's Republic of China)
,
Lv, Hong‐Ying
(Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, People's Republic of China)
,
Hao, Chen‐Xing
(Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, People's Republic of China)
,
Li, Tian‐Jun
(Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, People's Republic of China)
,
Zhu, Jing‐Juan
(Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, People's Republic of China)
,
Zhu, Hua
(Department of Medical Oncology, the Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, People's Republic of China)
,
Jiang, Man
(Department of Medical Oncology, the Affil)
,
Liu, Ke‐Wei
,
Hou, He‐Lei
,
Liu, Dong
,
Li, Ai‐Qin
,
Zhang, Guo‐Qing
,
Tian, Zi‐Bin
,
Zhang, Xiao‐Chun
Using the updated version of IBM Watson for Oncology, this study explored the concordance of the suggested therapeutic regimen between Watson and physicians in China. This article reports results and suggests some similarities and differences between the East and West in the treatment of cancer.Back...
Using the updated version of IBM Watson for Oncology, this study explored the concordance of the suggested therapeutic regimen between Watson and physicians in China. This article reports results and suggests some similarities and differences between the East and West in the treatment of cancer.Background.IBM Watson for Oncology (WFO), which can use natural language processing to evaluate data in structured and unstructured formats, has begun to be used in China. It provides physicians with evidence‐based treatment options and ranks them in three categories for treatment decision support. This study was designed to examine the concordance between the treatment recommendation proposed by WFO and actual clinical decisions by oncologists in our cancer center, which would reflect the differences of cancer treatment between China and the U.S.Patients and Methods.Retrospective data from 362 patients with cancer were ingested into WFO from April 2017 to October 2017. WFO recommendations were provided in three categories: recommended, for consideration, and not recommended. Concordance was analyzed by comparing the treatment decisions proposed by WFO with those of the multidisciplinary tumor board. Concordance was achieved when the oncologists' treatment decisions were in the recommended or for consideration categories in WFO.Results.Ovarian cancer showed the highest concordance, which was 96%. Lung cancer and breast cancer obtained a concordance of slightly above 80%. The concordance of rectal cancer was 74%, whereas colon cancer and cervical cancer showed the same concordance of 64%. In particular, the concordance of gastric cancer was very low, only 12%, and 88% of cases were under physicians choice.Conclusion.Different cancer types showed different concordances, and only gastric cancers were significantly less likely to be concordant. Incidence and pharmaceuticals may be the major cause of discordance. To be comprehensively and rapidly applied in China, WFO needs to accelerate localization. ClinicalTrials.gov Identifier: NCT03400514.Implications for Practice.IBM Watson for Oncology (WFO) has begun to be used in China. In this study, concordance was examined between the treatment recommendation proposed by WFO and clinical decisions for 362 patients in our cancer center, which could reflect the differences of cancer treatment between China and the U.S. Different cancer types showed different concordances, and only gastric cancers were significantly less likely to be concordant. Incidence and pharmaceuticals may be the major causes of discordance. To be comprehensively and rapidly applied in China, WFO needs to accelerate localization. This study may have a significant effect on application of artificial intelligence systems in China.
Using the updated version of IBM Watson for Oncology, this study explored the concordance of the suggested therapeutic regimen between Watson and physicians in China. This article reports results and suggests some similarities and differences between the East and West in the treatment of cancer.Background.IBM Watson for Oncology (WFO), which can use natural language processing to evaluate data in structured and unstructured formats, has begun to be used in China. It provides physicians with evidence‐based treatment options and ranks them in three categories for treatment decision support. This study was designed to examine the concordance between the treatment recommendation proposed by WFO and actual clinical decisions by oncologists in our cancer center, which would reflect the differences of cancer treatment between China and the U.S.Patients and Methods.Retrospective data from 362 patients with cancer were ingested into WFO from April 2017 to October 2017. WFO recommendations were provided in three categories: recommended, for consideration, and not recommended. Concordance was analyzed by comparing the treatment decisions proposed by WFO with those of the multidisciplinary tumor board. Concordance was achieved when the oncologists' treatment decisions were in the recommended or for consideration categories in WFO.Results.Ovarian cancer showed the highest concordance, which was 96%. Lung cancer and breast cancer obtained a concordance of slightly above 80%. The concordance of rectal cancer was 74%, whereas colon cancer and cervical cancer showed the same concordance of 64%. In particular, the concordance of gastric cancer was very low, only 12%, and 88% of cases were under physicians choice.Conclusion.Different cancer types showed different concordances, and only gastric cancers were significantly less likely to be concordant. Incidence and pharmaceuticals may be the major cause of discordance. To be comprehensively and rapidly applied in China, WFO needs to accelerate localization. ClinicalTrials.gov Identifier: NCT03400514.Implications for Practice.IBM Watson for Oncology (WFO) has begun to be used in China. In this study, concordance was examined between the treatment recommendation proposed by WFO and clinical decisions for 362 patients in our cancer center, which could reflect the differences of cancer treatment between China and the U.S. Different cancer types showed different concordances, and only gastric cancers were significantly less likely to be concordant. Incidence and pharmaceuticals may be the major causes of discordance. To be comprehensively and rapidly applied in China, WFO needs to accelerate localization. This study may have a significant effect on application of artificial intelligence systems in China.
참고문헌 (8)
Oncol Rep Makedon 15 971 2006 Overview: Computational analysis and decision support systems in oncology
J Clin Oncol Somashekhar 35 suppl 15 8527A 2017 10.1200/JCO.2017.35.15_suppl.8527 Early experience with IBM Watson for Oncology (WFO) cognitive computing system for lung and colorectal cancer treatment
Ann Oncol Zhang 28 suppl 10 544PA 2017 Concordance study between IBM Watson for Oncology (WFO) and clinical practice for breast and lung cancer patients in China
ESMO Open Curioni-Fontecedro 2 2017 10.1136/esmoopen-2017-000198 A new era of oncology through artificial intelligence
Curr Cariol Rep Dilsizian 16 441 2014 10.1007/s11886-013-0441-8 Artificial intelligence in medicine and cardiac imaging: Harnessing big data and advanced computing to provide personalized medical diagnosis and treatment
Ann Oncol Somashekhar 29 418 2018 10.1093/annonc/mdx781 Watson for Oncology and breast cancer treatment recommendations: Agreement with an expert multidisciplinary tumor board
J Clin Oncol Baek 35 suppl 15 2017 Use of a cognitive computing system for treatment of colon and gastric cancer in Korea
J Clin Oncol Jones 27 1177 2009 10.1200/JCO.2008.18.4028 Doxetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735
AI-Helper
※ AI-Helper는 부적절한 답변을 할 수 있습니다.